ERBB2 and breast carcinoma: Interestingly, B002T‐LP004 demonstrated significantly greater potency than equal doses of DS8201 and T‐DM1 in both the HER‐2‐resistant JIMT/CB17SCID immunodeficient murine breast cancer model and the MC38‐hHER2/C57 immunocompetent murine colorectal cancer model (Figure 2C, D).